Table: Tubulin inhibitors with their binding sites, therapeutic uses and stages of clinical development.[1][16] Classes of tubulin inhibitors Binding domain Related drugs or analogs Therapeutic uses Stage of clinical development Polymerization inhibitors Vinca domain Vinblastine Hodgkin's disease, testicular germ cell cancer in clinical use; 22 combination trials in progress Vincristine Leukemia, lymphomas In clinical use; 108 combination trials in progress Vinorelbine Solid tumours, lymphomas, lung cancer In clinical use; 29 phase I–III clinical trials in progress (single and combination) Vinflunine Bladder, non-small-cell lung cancer, breast cancer Phase III Crytophycin 52 Solid tumours Phase III finished Halichondrins - Phase I Dolastatins Potential vascular-targeting agent Phase I; phase II completed Hemiasterlins - Phase I Colchicine domain Colchicine Non-neoplastic diseases (gout, familial mediterranean fever) Approved in 2009 by FDA under the Unapproved Drugs Initiative[citation needed] Combretastatins Potential vascular-targeting agent Phase I 2-Methoxyestradiol - Phase I E7010 Solid tumours Phase I, II Depolymerization inhibitors Taxan site Paclitaxel (Taxol) Ovarian, breast and lung tumours, Kaposi's sarcoma; trials with numerous other tumours In clinical use; 207 Phase I–III trials in the United States; TL00139 is in Phase I trials Docetaxel (Taxotere) Prostate, brain and lung tumours 8 trials in the United States (Phases I–III) Epothilone Paclitaxel-resistant tumours Phases I–III Discodermolide - Phase I